245 related articles for article (PubMed ID: 17453956)
21. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study.
Hernandez RK; Sørensen HT; Pedersen L; Jacobsen J; Lash TL
Cancer; 2009 Oct; 115(19):4442-9. PubMed ID: 19569248
[TBL] [Abstract][Full Text] [Related]
22. Tamoxifen exposure in relation to gastric adenocarcinoma development.
Chandanos E; Lindblad M; Rubio CA; Jia C; Warner M; Gustafsson JA; Lagergren J
Eur J Cancer; 2008 May; 44(7):1007-14. PubMed ID: 18394879
[TBL] [Abstract][Full Text] [Related]
23. [Birdshot chorioretinopathy associated with tamoxifen retinal toxicity].
Sommer S; Badet JC; Zaoui M; Naoun-Hubert I; Rozot P
J Fr Ophtalmol; 2000 May; 23(5):494-7. PubMed ID: 10844311
[TBL] [Abstract][Full Text] [Related]
24. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L;
Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242
[TBL] [Abstract][Full Text] [Related]
25. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
26. The multifocal pattern electroretinogram in chloroquine retinopathy.
Neubauer AS; Stiefelmeyer S; Berninger T; Arden GB; Rudolph G
Ophthalmic Res; 2004; 36(2):106-13. PubMed ID: 15017107
[TBL] [Abstract][Full Text] [Related]
27. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy.
Lai TY; Chan WM; Li H; Lai RY; Lam DS
Am J Ophthalmol; 2005 Nov; 140(5):794-807. PubMed ID: 16310457
[TBL] [Abstract][Full Text] [Related]
28. Abnormal multifocal electroretinogram (mfERG) in ethambutol toxicity.
Kardon RH; Morrisey MC; Lee AG
Semin Ophthalmol; 2006; 21(4):215-22. PubMed ID: 17182409
[TBL] [Abstract][Full Text] [Related]
29. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen.
Kesim MD; Aydin Y; Atis A; Mandiraci G
Climacteric; 2008 Jun; 11(3):252-7. PubMed ID: 18568790
[TBL] [Abstract][Full Text] [Related]
30. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
Osborne CR; Duncan A; Sedlacek S; Paul D; Holmes F; Vukelja S; Kasper M; Wilks S; Schneider A; McGee R; Meyer WG; O'Shaughnessy JA
Breast Cancer Res Treat; 2009 Aug; 116(3):521-7. PubMed ID: 19139988
[TBL] [Abstract][Full Text] [Related]
31. Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin.
Yuvaraj S; Premkumar VG; Vijayasarathy K; Gangadaran SG; Sachdanandam P
Cancer Chemother Pharmacol; 2008 May; 61(6):933-41. PubMed ID: 17668211
[TBL] [Abstract][Full Text] [Related]
32. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
33. Myxoid leiomyosarcoma of the uterus in a patient receiving tamoxifen therapy: a case report.
Botsis D; Koliopoulos C; Kondi-Pafitis A; Creatsas G
Int J Gynecol Pathol; 2006 Apr; 25(2):173-5. PubMed ID: 16633068
[TBL] [Abstract][Full Text] [Related]
34. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
[TBL] [Abstract][Full Text] [Related]
35. Ocular toxicity of tamoxifen.
Gerner EW
Ann Ophthalmol; 1989 Nov; 21(11):420-3. PubMed ID: 2619152
[TBL] [Abstract][Full Text] [Related]
36. Retinal hemorrhages in anastrozole users.
Eisner A; Falardeau J; Toomey MD; Vetto JT
Optom Vis Sci; 2008 May; 85(5):301-8. PubMed ID: 18451730
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
[TBL] [Abstract][Full Text] [Related]
38. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
Johansen J; Overgaard J; Overgaard M
Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
[TBL] [Abstract][Full Text] [Related]
39. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
Kaufmann M; Jonat W; Hilfrich J; Eidtmann H; Gademann G; Zuna I; von Minckwitz G
J Clin Oncol; 2007 Jul; 25(19):2664-70. PubMed ID: 17563395
[TBL] [Abstract][Full Text] [Related]
40. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study.
Hermelink K; Henschel V; Untch M; Bauerfeind I; Lux MP; Munzel K
Cancer; 2008 Nov; 113(9):2431-9. PubMed ID: 18823033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
